{
    "eightKs": [
        {
            "content": "Termination of a Material Definitive Agreement. On December 16, 2020, ProPhase Labs, Inc. (the \u201cCompany\u201d) gave notice to A.G.P./Alliance Global Partners (\u201cAGP\u201d) of its election to terminate the Sales Agreement, dated September 23, 2020, by and between the Company and AGP (the \u201cSales Agreement\u201d). Pursuant to such notice, the Sales Agreement will terminate effective as of 5:00 p.m. (Eastern time) on Monday, December 21, 2020. Pursuant to the Sales Agreement and the Prospectus Supplement dated September 23, 2020, the Company was entitled to offer and sell, from time to time through AGP, up to $11,343,248 shares of its common stock, par value $0.0005 per share, in an \u201cat-the-market\u201d offering program (the \u201cATM Program\u201d). No sales have been made under the ATM Program.   Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc.  By:",
            "date": "2020-12-16",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315220023760/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Regulation FD Disclosure. On March 15, 2021, ProPhase Labs, Inc. (the \u201cCompany\u201d) issued a press release announcing that it will host a conference call on March 31, 2021 at 4:30 p.m. (Eastern Time) to discuss its financial results for the fourth quarter and full year ended December 31, 2020. The information in this Current Report on Form 8-K, including the exhibit, is being furnished and shall not be deemed \u201cfiled\u201d for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. Item 9.01 Financial Statements and Exhibits. (d) Exhibits  Exhibit Number  Exhibit Table   99.1  Press Release issued by ProPhase Labs, Inc., dated March 15, 2021.  Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be sign",
            "date": "2021-03-17",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221006226/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Regulation FD Disclosure. On February 1, 2021, ProPhase Labs, Inc. (the \u201cCompany\u201d) issued a press release announcing that it will host a shareholder conference call on February 10, 2021 at 11:00 a.m. (Eastern Time) to review the performance of the Company\u2019s laboratory processing business, short- and long-term prospects for future growth, and strategic direction. The information in this Current Report on Form 8-K, including the exhibit, is being furnished and shall not be deemed \u201cfiled\u201d for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. Item 9.01 Financial Statements and Exhibits.  (d) Exhibits  Exhibit Number  Exhibit Table   99.1  Press Release issued by ProPhase Labs, Inc., dated February 1, 2021.  Pursuant to the requirements of the Secur",
            "date": "2021-02-01",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221002173/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Entry into a Material Definitive Agreement. On January 18, 2021, ProPhase Labs, Inc. (the \u201cCompany\u201d) entered into an underwriting agreement (the \u201cUnderwriting Agreement\u201d) with ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the underwriters (the \u201cUnderwriters\u201d), relating to the public offering (the \u201cOffering\u201d) of 3 million shares of common stock of the Company, $0.0005 par value per share, at a price to the public of $12.50 per share. The net proceeds to the Company from the Offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $35.1 million. The Offering is expected to close on or about January 21, 2021, subject to customary closing conditions. Under the terms of the Underwriting Agreement, the Company has also granted the Underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offe",
            "date": "2021-01-20",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221001435/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Entry into a Material Definitive Agreement. On January 14, 2021, ProPhase Labs, Inc. (the \u201cCompany\u201d) entered into an Amendment and Termination Agreement (the \u201cAgreement\u201d) with Predictive Laboratories, Inc. (\u201cPredictive\u201d), pursuant to which the parties amended that certain Amended and Restated Promissory Note and Security Agreement by and between the parties, dated September 25, 2020. Pursuant to the terms of the Agreement, the Company has loaned an additional $1 million to Predictive in consideration for Predictive\u2019s agreement to cancel its existing consulting agreement with the Company, dated September 25, 2020 (the \u201cConsulting Agreement\u201d), and terminate the Company\u2019s obligation to pay Predictive additional consulting fees beyond the $250,000 already earned by Predictive under the Consulting Agreement. As a result, the initial principal amount due under the Note was increased from $3 million to $3.75 million plus all accrued and unpaid interest arising under the No",
            "date": "2021-01-15",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221001124/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "Entry into a Material Definitive Agreement. On January 5, 2021, ProPhase Labs, Inc. (the \u201cCompany\u201d) entered into a securities purchase agreement (the \u201cSecurities Purchase Agreement\u201d) with certain accredited investors and qualified institutional buyers (the \u201cPurchasers\u201d), pursuant to which the Company agreed to issue and sell to the Purchasers an aggregate of (i) 550,000 shares (the \u201cShares\u201d) of its common stock, par value $0.0005 per share (the \u201cCommon Stock\u201d), and (ii) warrants to purchase up to 275,000 shares of Common Stock (the \u201cWarrants\u201d) in a registered direct offering (the \u201cRegistered Direct Offering\u201d). The Shares are being sold at a purchase price of $10.00 per share. Each Warrant has an exercise price equal to $11.00 per share of Common Stock, will be exercisable at any time and from time to time, subject to certain conditions described in the Warrant, after the date of issuance, and will expire on the date that is three years from the date of issua",
            "date": "2021-01-07",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221000410/form8-k.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        },
        {
            "content": "therein as provided herein. At the time of filing of the Original Form 8-K disclosing the acquisition by ProPhase Diagnostics, Inc., a wholly-owned subsidiary of the Company, of all of the issued and outstanding shares of capital stock of Confucius Plaza Medical Laboratory Corp. (\u201cConfucius\u201d) owned by Pride Diagnostics LLC, the Company indicated that it would file the necessary financial information within 71 days after the date that the Original Form 8-K was required to be filed. Upon further review, the Company has determined that financial statements required by Item 9.01(a) and pro forma financial information required by Item 9.01(b) with respect to the acquisition of Confucius are not required because the acquisition was not a \u201csignificant\u201d transaction as defined in Regulation S-X. Accordingly, the Company hereby amends the Original Form 8-K to eliminate references to the subsequent filing of financial statements and pro forma financial information relating to the acquisit",
            "date": "2021-01-04",
            "details": "",
            "filingType": "8-K",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315221000072/form8-ka.htm",
            "nonComplianceType": "",
            "nonCompliant": false,
            "tags": []
        }
    ],
    "importantItems": [
        {
            "date": "03/30/2021",
            "details": "ProPhase Labs Acquires Digital Covid Vaccination and Testing Passport Solution",
            "kind": "",
            "nonCompliant": false,
            "sourceLink": "https://finance.yahoo.com/news/prophase-labs-acquires-digital-covid-211000071.html",
            "sourceType": "Press Release",
            "tag": ""
        }
    ],
    "na": false,
    "ownership": {
        "calculatedFloat": 0,
        "date": "",
        "footnotes": null,
        "rows": null,
        "sharesOutstanding": 0,
        "source": "",
        "sourceType": "",
        "sumActual": 0,
        "textbookFloat": 0
    },
    "shelfs": [
        {
            "baseType": "S-3",
            "effective": "2018-07-05 16:30:00",
            "exemptOffering": false,
            "expirationDate": "2021-07-04 16:30:00 +0000 UTC",
            "expired": false,
            "fileID": "333-225875",
            "filings": [
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": true,
                    "addToRemaining": false,
                    "aggregateAmount": 37500000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2021-01-20",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001400/form424b5.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-225875",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-225875&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "67954545",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "149500000",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "Fordham Financial Management",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 2.2,
                    "remaining": 20656752,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 3000000,
                    "sharesOutstanding": "9,343,216",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": [
                        "275,000@$11.00",
                        "275,000@$11.00",
                        "400,000@$3.00"
                    ]
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": true,
                    "addToRemaining": false,
                    "aggregateAmount": 0,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2021-01-15",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001194/form424b5.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-225875",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-225875&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "67909091",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "149400000",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "Fordham Financial Management",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 2.2,
                    "remaining": 58156752,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "9,343,216",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": true,
                    "warrants": [
                        "275,000@$11.00",
                        "275,000@$11.00",
                        "400,000@$3.00"
                    ]
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": true,
                    "addToRemaining": false,
                    "aggregateAmount": 5500000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2021-01-06",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315221000344/form424b5.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-225875",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-225875&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "8763838",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "95000000",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 10,
                    "remaining": 58156752,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 550000,
                    "sharesOutstanding": "8,793,216",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": [
                        "275,000@$11.00",
                        "275,000@$11.00",
                        "275,000@$11.00"
                    ]
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": true,
                    "addToRemaining": false,
                    "aggregateAmount": 11343248,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2020-09-23",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315220018227/form424b5.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-225875",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-225875&owner=exclude&count=40",
                    "filingType": "424B5",
                    "float": "10127900",
                    "foreign": false,
                    "hasATM": true,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "$34,029,745",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "A.G.P.",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 3.36,
                    "remaining": 63656752,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "8,793,216",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": []
                },
                {
                    "AmountSold": 0,
                    "AtmIncreased": false,
                    "IsLatestPreliminary": false,
                    "IsSupplement": false,
                    "addToRemaining": false,
                    "aggregateAmount": 75000000,
                    "amendmentType": "",
                    "atmRemaining": 0,
                    "date": "2018-06-25",
                    "documentUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315218009178/forms-3.htm",
                    "error": "",
                    "explanatoryNote": "",
                    "fileID": "333-225875",
                    "fileUrl": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-225875&owner=exclude&count=40",
                    "filingType": "S-3",
                    "float": "8,479,851 ",
                    "foreign": false,
                    "hasATM": false,
                    "hasResale": false,
                    "hasResaleBase": false,
                    "hasResaleSupplement": false,
                    "hiddenATM": "",
                    "ib6": "0",
                    "isAmendment": false,
                    "isHybrid": false,
                    "isIPO": false,
                    "mvphs": "25400000",
                    "offeringInfo": "",
                    "offeringType": "",
                    "placementAgent": "",
                    "prefundedExercise": "",
                    "prefundedWarrants": "",
                    "price": 2.99,
                    "remaining": 75000000,
                    "resaleAggregate": 0,
                    "resaleShares": "",
                    "sharesOffered": 0,
                    "sharesOutstanding": "11,534,571",
                    "sharesOutstandingPrior": "",
                    "show": true,
                    "subjectToCompletion": false,
                    "warrants": null
                }
            ],
            "foreign": false,
            "hasATM": true,
            "hasHiddenATM": false,
            "isIPO": false,
            "latestFilingDate": "2021-01-20",
            "show": true
        }
    ],
    "stockInfo": {
        "exchange": "NASDAQ",
        "float": "9.45M",
        "income": "-1.70M",
        "io": "3.20%",
        "marketCap": "94.24M",
        "name": "ProPhase Labs, Inc.",
        "news": [
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-acquires-digital-covid-211000071.html",
                "date": "Mar-30-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Acquires Digital Covid Vaccination and Testing Passport Solution"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-host-fourth-quarter-123000355.html",
                "date": "Mar-15-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-begins-advanced-saliva-133000117.html",
                "date": "Feb-09-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Begins Advanced, Saliva-based Viral PCR Multiplex-Testing for COVID-19, Influenza A & B, and Other Viruses After FDA Confirmation of Two Emergency Use Authorizations"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-exceeding-initial-goals-133000074.html",
                "date": "Feb-01-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Exceeding Initial Goals as Covid-19 Lab Testing Business Ramps up"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-opening-large-133000483.html",
                "date": "Jan-29-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-inc-announces-closing-213000803.html",
                "date": "Jan-21-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs, Inc. Announces Closing of Public Offering"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-pricing-public-025000576.html",
                "date": "Jan-18-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces Pricing of Public Offering of Common Stock"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-proposed-public-222100349.html",
                "date": "Jan-15-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces Proposed Public Offering of Common Stock"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-present-noblecon17-annual-133000313.html",
                "date": "Jan-11-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs to Present at the NobleCon17 Annual Small & Microcap Investor Conference on Tuesday, January 19, 2021 at 12:45 p.m. Eastern Time"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-5-5-171000648.html",
                "date": "Jan-05-21 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces $5.5 Million Registered Direct Offering of Common Stock and Warrants"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-expands-covid-19-211500931.html",
                "date": "Dec-08-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Expands COVID-19 Testing Capacity with New 25,000 Square Feet Testing Facility in Garden City, New York"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-reports-financial-results-133000414.html",
                "date": "Nov-16-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2020"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-present-virtual-fall-133000274.html",
                "date": "Nov-10-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-completes-acquisition-clia-133000159.html",
                "date": "Nov-02-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Completes Acquisition of CLIA Accredited Lab and Provides Corporate Update"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-definitive-agreement-123000970.html",
                "date": "Oct-23-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces Definitive Agreement to Acquire CLIA Accredited Lab Certified for COVID-19 and Upper Respiratory Testing"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-engages-industry-expert-210400013.html",
                "date": "Sep-30-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Engages Industry Expert to Advise on Possible Acquisition of CLIA Accredited Labs Certified for COVID-19 and Other Testing"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-engages-mz-group-123000015.html",
                "date": "Sep-30-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-announces-10-million-120000361.html",
                "date": "Sep-18-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Announces $10 Million Unsecured Debt Financing"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-reports-financial-results-124700856.html",
                "date": "Aug-11-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2020"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-reports-financial-results-120010007.html",
                "date": "May-12-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Reports Financial Results for the Three Months Ended March 31, 2020"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-reports-financial-results-123610834.html",
                "date": "Mar-25-20 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Reports Financial Results for the Year Ended December 31, 2019"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-inc-announces-special-211500248.html",
                "date": "Nov-20-19 ",
                "source": "GlobeNewswire",
                "text": "PROPHASE LABS, INC. ANNOUNCES SPECIAL CASH DIVIDEND"
            },
            {
                "anchor": "https://finance.yahoo.com/news/prophase-labs-reports-financial-results-143500506.html",
                "date": "Nov-12-19 ",
                "source": "GlobeNewswire",
                "text": "ProPhase Labs Reports Financial Results for the Three Months and Nine Months Ended September 30, 2019"
            }
        ],
        "price": "6.27",
        "profile": "ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers COVID-19 and other respiratory pathogen panel testing services. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.",
        "sectorsAndCountry": "Healthcare | Drug Manufacturers - Specialty & Generic | USA",
        "sharesOutstanding": "11.60M",
        "shortOfFloat": "1.29%",
        "sixtyDayVWAP": 16,
        "symbol": "PRPH",
        "url": "https://finviz.com/quote.ashx?t=PRPH"
    },
    "tenQ": {
        "filingType": "10-Q",
        "iXBRL": false,
        "stats": {
            "balanceSheetHTML": "",
            "balanceSheetUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315220022041/R2.htm",
            "cash": "10.8M",
            "cashBurnMonthly": "N/A",
            "cashFlowHTML": "",
            "cashFlowUrl": "https://www.sec.gov/Archives/edgar/data/868278/000149315220022041/R7.htm",
            "cashLeft": "N/A",
            "cashUsed": "N/A",
            "currentRatio": 8.35,
            "date": "Sep. 30, 2020",
            "isNegative": false,
            "monthsOfCash": "N/A",
            "na": false,
            "netCashOperating": "4.1M",
            "quickRatio": 5.06,
            "sharesOutstanding": "",
            "totalCurrentAssets": "17.9M",
            "totalCurrentLiabilities": "2.1M"
        },
        "tenQDocument": {
            "content": "",
            "conversionPrices": [
                "3.00"
            ],
            "lagcT": "Liquidity\nand Capital Resources",
            "link": "https://www.sec.gov//Archives/edgar/data/868278/000149315220022041/form10-q.htm",
            "liquidityAndGoingConcern": "Our aggregate cash and cash equivalents and marketable debt securities as of September 30, 2020 was $12.3 million as compared to $1.4 million at December 31, 2019. Our working capital was $15.8 million and $9.0 million as of September 30, 2020 and December 31, 2019, respectively. The increase of $10.9 million in our cash and cash equivalents and marketable debt securities balance for the nine months ended September 30, 2020 was principally due to the release of the escrow funds of $4.8 million by Mylan and issuance of the unsecured convertible September 2020 Notes payable for an aggregate principal amount of $10.0 million offset by entering into Secured Note receivable with a consultant for $3.0 million.  We believe our current working capital is an acceptable and adequate level of working capital to support our business for at least the next twelve months after the date that the unaudited condensed consolidated financial statements are issued.  COVID-19  The COVID-19 pandemic has not had a material impact on our business to date, although we did experience higher than normal net sales for the three and nine months ended September 30, 2020, primarily as a result of increased customer demand for our OTC healthcare and cold remedy products as a result of the COVID-19 pandemic.  On October 23, 2020, we acquired a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory that offers a variety of important medical tests, including, among others, COVID-19 diagnostic tests. While we expect revenues to increase as result of our new business line, we will need to make substantial investments to secure the necessary equipment, supplies and personnel to provide these testing services. There can be no assurance that our efforts to offer and perform COVID-19 testing will be successful and that we will be able to generate a profit.  The ultimate impact of COVID-19 on... (See filing for more info)"
        }
    },
    "ticker": "PRPH",
    "timelines": {
        "float": [
            {
                "amount": 8479851,
                "date": "2018-06-25",
                "filingType": "S-3",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315218009178/forms-3.htm",
                "tag": ""
            },
            {
                "amount": 10127900,
                "date": "2020-09-23",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315220018227/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 8763838,
                "date": "2021-01-06",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221000344/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 67909091,
                "date": "2021-01-15",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001194/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 67954545,
                "date": "2021-01-20",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001400/form424b5.htm",
                "tag": ""
            }
        ],
        "os": [
            {
                "amount": 11534571,
                "date": "2018-06-25",
                "filingType": "S-3",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315218009178/forms-3.htm",
                "tag": ""
            },
            {
                "amount": 8793216,
                "date": "2020-09-23",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315220018227/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 11604253,
                "date": "Sep. 30, 2020",
                "filingType": "10-Q",
                "sourceID": "",
                "sourceLink": "https://www.sec.gov//Archives/edgar/data/868278/000149315220022041/form10-q.htm",
                "tag": ""
            },
            {
                "amount": 8793216,
                "date": "2021-01-06",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221000344/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 9343216,
                "date": "2021-01-15",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001194/form424b5.htm",
                "tag": ""
            },
            {
                "amount": 9343216,
                "date": "2021-01-20",
                "filingType": "424B5",
                "sourceID": "333-225875",
                "sourceLink": "https://www.sec.gov/Archives/edgar/data/868278/000149315221001400/form424b5.htm",
                "tag": ""
            }
        ]
    }
}